Literature DB >> 21091111

Immunotherapy through T-cell receptor gene transfer induces severe graft-versus-host disease.

James Ferrara1, Pavan Reddy, Sophie Paczesny.   

Abstract

Evaluation of: Bendle GM, Linnemann C, Hooijkaas AI et al.: Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16(5), 565-570 (2010). Graft-versus-host disease is commonly associated with allogeneic hematopoietic cell transplantation, as it is the major complication. This article reports that, after immunotherapy with lymphocytes that have been transduced with T-cell receptor (TCR) genes of known specificity, graft-versus-host disease can occur through TCR gene transfer. This autoimmune pathology occurs through the formation of self-reactive TCRs as a result of one chain of the transduced TCR cross-pairing with an endogenous TCR. Certain adjustments in the design of gene therapy vectors may help reduce the risk of such autoimmune phenomena.

Entities:  

Year:  2010        PMID: 21091111      PMCID: PMC3448368          DOI: 10.2217/imt.10.73

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  23 in total

1.  Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

Authors:  Juhua Zhou; Xinglei Shen; Jianping Huang; Richard J Hodes; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

Review 2.  Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current use of irradiated blood products.

Authors:  B H Greenbaum
Journal:  J Clin Oncol       Date:  1991-10       Impact factor: 44.544

Review 3.  T-lymphocyte-antigen interactions in transplant rejection.

Authors:  A M Krensky; A Weiss; G Crabtree; M M Davis; P Parham
Journal:  N Engl J Med       Date:  1990-02-22       Impact factor: 91.245

4.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.

Authors:  Dori A Thomas; Joan Massagué
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

5.  Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy.

Authors:  P de Felipe; V Martín; M L Cortés; M Ryan; M Izquierdo
Journal:  Gene Ther       Date:  1999-02       Impact factor: 5.250

Review 6.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

Review 7.  Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".

Authors:  Gianpietro Dotti; Barbara Savoldo; Malcolm Brenner
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

8.  The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.

Authors:  J H Donohue; M Rosenstein; A E Chang; M T Lotze; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

9.  Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

Authors:  Cyrille J Cohen; Yong F Li; Mona El-Gamil; Paul F Robbins; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

10.  Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer.

Authors:  Mirjam H M Heemskerk; Manja Hoogeboom; Renate Hagedoorn; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg
Journal:  J Exp Med       Date:  2004-03-29       Impact factor: 14.307

View more
  2 in total

1.  Sarcoma Tumor Microenvironment.

Authors:  Panagiotis Tsagozis; Jordi Gonzalez-Molina; Anna-Maria Georgoudaki; Kaisa Lehti; Joseph Carlson; Andreas Lundqvist; Felix Haglund; Monika Ehnman
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 2.  TCR-T Immunotherapy: The Challenges and Solutions.

Authors:  Yating Liu; Xin Yan; Fan Zhang; Xiaoxia Zhang; Futian Tang; Zhijian Han; Yumin Li
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.